check_circleStudy Completed

Female contraception

Bayer Identifier:

13190

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2009-013082-25

EU CT Number:

Not Available
DRSP Wafer: Rel. BA DRSP + buccal E2

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 75 Years
  • -

  • -

Trial summary

Enrollment Goal
12
Trial Dates
November 2009 - January 2010
Phase
Phase 1
Could I Receive a placebo
N/A
Products
DRSP Ring (BAY86-4888)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

An exploratory, open-label, single-dose, randomized, crossover study investigating the relative bioavailability of drospirenone (DRSP) and estradiol (E2) after oral single dose administration of 3 mg DRSP and 90 μg E2 as a wafer formulation versus a marketed tablet (ANGELIQ) in 12 healthy postmenopausal women
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.